How Commonly Does Parkinson’s Disease Present with Dystonia?
Objective: To review dystonia as the presenting feature of Parkinson’s disease (PD). Background: Dystonia in PD is most commonly described as a levodopa complication. It…7,8- Dihydroxyflavone prevents 3-NitropropionicAcid (3-NP)-induced Striatal Toxicity by Modulating the TrkB receptor and Microglial Activation Pathway
Objective: Hungtion’s disease (HD) is an autosomal governing neurodegenerative disorder caused by production of mutant hungtingtin(Htt) protein followed by death of the GABAergic neurons in…MRI, Clinical, and Neuropathological Findings after Bilateral Intra-striatal Administration of rAAV5-miHTT in Non-human Primates
Objective: To assess the effects of intra-striatal administration of a huntingtin protein (HTT) lowering gene therapy in macaca fascicularis non-human primates (NHP). Background: The aggregation…Multimodal characterization of the visual network in Huntington’s disease
Objective: To examine the relationship between structural organization, functional processing and task performance of the visual system in a cohort of Huntington’s disease (HD) gene-mutation…Using functional status to aid interpretation of cUHDRS scores in patients with Huntington’s disease
Objective: To enhance understanding of the composite Unified Huntington’s Disease Rating Scale (cUHDRS) scoring by linking to established measures of meaningful daily function and independence…Systematic review of Mucuna Pruriens as a treatment for Parkinson’s disease
Objective: To conduct a systematic review of the therapeutic evidence for Mucuna Pruriens (MP) in the treatment of Parkinson’s disease (PD). Background: MP or Velvet bean is a…Laboratory Performance of the DopaFuse® Delivery System
Objective: SynAgile has developed the DopaFuse Delivery System to noninvasively and continuously administer levodopa/carbidopa (LD/CD) into the mouths of patients with Parkinson’s Disease (PD). The…Olfactory Hallucinations Induced by Pramipexole Treatment in Parkinson’s Disease
Objective: In the treatment of Parkinson’s disease, dopamine agonists are among the preferred treatment options, particularly in the treatment of young Parkinson’s patients. The known…Formulations and evaluations of Intranasal Nose to Brain Delivery of Curcumin with resveratrol Nanoparticle for treatment of Parkisonism
Objective: Parkinson’s disease (PD) is a common neurodegenerative disease characterized by motor symptoms of tremor, rigidity, bradykinesia, and postural instability. Growing evidence indicates that resveratrol…Efficacy of opicapone in Parkinson’s disease patients according to baseline pramipexole use: a post-hoc analysis from combined BIPARK-I and II.
Objective: To evaluate opicapone’s (OPC) efficacy in levodopa-treated Parkinson’s Disease (PD) patients with or without concurrent pramipexole use (CPU). Background: OPC, a once-daily COMT inhibitor,…
- « Previous Page
- 1
- …
- 57
- 58
- 59
- 60
- 61
- …
- 217
- Next Page »